| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A brave new framework for glioma drug development
|
Hotchkiss, Kelly M
|
|
|
25 |
10 |
p. e512-e519
|
artikel
|
| 2 |
Adverse obstetric outcomes in female survivors of adolescent and young adult cancers
|
Tang, Weizhen
|
|
|
25 |
10 |
p. e465
|
artikel
|
| 3 |
Adverse obstetric outcomes in female survivors of adolescent and young adult cancers
|
Cui, Ying
|
|
|
25 |
10 |
p. e466
|
artikel
|
| 4 |
Adverse obstetric outcomes in female survivors of adolescent and young adult cancers
|
Huang, Yizhuan
|
|
|
25 |
10 |
p. e467
|
artikel
|
| 5 |
Adverse obstetric outcomes in female survivors of adolescentand young adult cancers – Authors' reply
|
Reulen, Raoul C
|
|
|
25 |
10 |
p. e468
|
artikel
|
| 6 |
A step closer to the use of [177Lu]Lu-PSMA-617 in metastatic hormone-sensitive prostate cancer
|
Jia, Angela Y
|
|
|
25 |
10 |
p. 1246-1247
|
artikel
|
| 7 |
Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): a multicentre, single-arm, phase 2 trial
|
Tedeschi, Alessandra
|
|
|
25 |
10 |
p. 1298-1309
|
artikel
|
| 8 |
Belzutifan for patients with von Hippel-Lindau disease-associated CNS haemangioblastomas (LITESPARK-004): a multicentre, single-arm, phase 2 study
|
Iliopoulos, Othon
|
|
|
25 |
10 |
p. 1325-1336
|
artikel
|
| 9 |
Best practices and novel approaches for the preclinical development of drug–radiotherapy combinations for cancer treatment
|
Prasanna, Pataje G S
|
|
|
25 |
10 |
p. e501-e511
|
artikel
|
| 10 |
Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial
|
Wolf, Jürgen
|
|
|
25 |
10 |
p. 1357-1370
|
artikel
|
| 11 |
Challenges and opportunities for early phase clinical trials of novel drug–radiotherapy combinations: recommendations from NRG Oncology, the American Society for Radiation Oncology (ASTRO), the American College of Radiology (ACR), the Sarah Cannon Research Institute, and the American College of Radiation Oncology (ACRO)
|
Zumsteg, Zachary S
|
|
|
25 |
10 |
p. e489-e500
|
artikel
|
| 12 |
Continued suboptimal HPV vaccine coverage in the USA
|
Burki, Talha
|
|
|
25 |
10 |
p. 1257
|
artikel
|
| 13 |
Correction to Lancet Oncol 2024; 25: 989–1002
|
|
|
|
25 |
10 |
p. e472
|
artikel
|
| 14 |
Development of a conceptual framework for an electronic patient-reported outcome (ePRO) system measuring symptoms and impacts of CAR T-cell therapies in patients with haematological malignancies
|
Khatsuria, Foram
|
|
|
25 |
10 |
p. e476-e488
|
artikel
|
| 15 |
Diagnostic accuracy of risk prediction models in postmenopausal patients with suspected ovarian cancer
|
Taskiran, Cagatay
|
|
|
25 |
10 |
p. 1251-1252
|
artikel
|
| 16 |
Efficacy and safety of immune checkpoint inhibitors for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review, meta-analysis, and network meta-analysis
|
Zhao, Yi
|
|
|
25 |
10 |
p. 1347-1356
|
artikel
|
| 17 |
ESMO Congress 2024
|
Lai, Cheryl
|
|
|
25 |
10 |
p. e474-e475
|
artikel
|
| 18 |
European Commission approval for Dutch investment in radiopharmaceuticals
|
Gruber, Karl
|
|
|
25 |
10 |
p. 1260
|
artikel
|
| 19 |
Families of cancer victims wait for benefits decades after the World Trade Center attack
|
Gruber, Karl
|
|
|
25 |
10 |
p. e473
|
artikel
|
| 20 |
Investigating hidden influences on treatment for gastrointestinal stromal tumours with AI: diet, chronic conditions, and mental health
|
Ma, Hanjun
|
|
|
25 |
10 |
p. e469
|
artikel
|
| 21 |
Investigating hidden influences on treatment for gastrointestinal stromal tumours with AI: diet, chronic conditions, and mental health – Authors' reply
|
Margonis, Georgios Antonios
|
|
|
25 |
10 |
p. e470
|
artikel
|
| 22 |
IVLBCL mimicking VEXAS syndrome
|
Shopsowitz, Kevin
|
|
|
25 |
10 |
p. e526
|
artikel
|
| 23 |
Losing my brother, finding myself
|
Morgan, Jules
|
|
|
25 |
10 |
p. 1265
|
artikel
|
| 24 |
Medicare drug price negotiations by the US Government
|
Devi, Sharmila
|
|
|
25 |
10 |
p. 1256
|
artikel
|
| 25 |
New developments in tobacco control measures in Europe
|
Burki, Talha
|
|
|
25 |
10 |
p. 1259
|
artikel
|
| 26 |
NHS cancer services and systems: critical support for cancer care
|
Morrison, David Stewart
|
|
|
25 |
10 |
p. e471
|
artikel
|
| 27 |
Palliative radiotherapy versus best supportive care in patients with painful hepatic cancer (CCTG HE1): a multicentre, open-label, randomised, controlled, phase 3 study
|
Dawson, Laura A
|
|
|
25 |
10 |
p. 1337-1346
|
artikel
|
| 28 |
Petition to end travel insurance discrimination against people with cancer
|
Das, Manjulika
|
|
|
25 |
10 |
p. 1261
|
artikel
|
| 29 |
Precision medicine with MET exon 14: a partial success
|
Chu, Quincy S-C
|
|
|
25 |
10 |
p. 1249-1251
|
artikel
|
| 30 |
Radiation oncology: a call for papers for ESTRO 2025
|
Collingridge, David
|
|
|
25 |
10 |
p. 1254-1255
|
artikel
|
| 31 |
Reviving the UK NHS: Labour's biggest challenge?
|
The Lancet Oncology,
|
|
|
25 |
10 |
p. 1245
|
artikel
|
| 32 |
Rising costs of cancer medicines
|
Devi, Sharmila
|
|
|
25 |
10 |
p. 1262
|
artikel
|
| 33 |
Risk-prediction models in postmenopausal patients with symptoms of suspected ovarian cancer in the UK (ROCkeTS): a multicentre, prospective diagnostic accuracy study
|
Sundar, Sudha
|
|
|
25 |
10 |
p. 1371-1386
|
artikel
|
| 34 |
Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study
|
Azad, Arun A
|
|
|
25 |
10 |
p. 1267-1276
|
artikel
|
| 35 |
Sintilimab combined with bevacizumab in relapsed or persistent ovarian clear cell carcinoma (INOVA): a multicentre, single-arm, phase 2 trial
|
Peng, Zikun
|
|
|
25 |
10 |
p. 1288-1297
|
artikel
|
| 36 |
The Cancer Tapestry is telling a thousand stories
|
Ranscombe, Peter
|
|
|
25 |
10 |
p. 1266
|
artikel
|
| 37 |
The tyranny of non-inferiority trials
|
Tannock, Ian F
|
|
|
25 |
10 |
p. e520-e525
|
artikel
|
| 38 |
The UK needs to be a leader, not a lagger, in the global cancer effort
|
Lawler, Mark
|
|
|
25 |
10 |
p. 1253-1254
|
artikel
|
| 39 |
Treatment of Richter transformation—immunotherapy to the rescue?
|
Al-Sawaf, Othman
|
|
|
25 |
10 |
p. 1248-1249
|
artikel
|
| 40 |
Using cancer to fuel art at the Edinburgh Festival Fringe
|
Ranscombe, Peter
|
|
|
25 |
10 |
p. 1263-1264
|
artikel
|
| 41 |
World's first lung cancer vaccine trial launched in the UK
|
Gourd, Elizabeth
|
|
|
25 |
10 |
p. 1258
|
artikel
|
| 42 |
Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial
|
Wang, Eunice S
|
|
|
25 |
10 |
p. 1310-1324
|
artikel
|
| 43 |
[89Zr]Zr-girentuximab for PET–CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trial
|
Shuch, Brian
|
|
|
25 |
10 |
p. 1277-1287
|
artikel
|
Tijdschrift beschrijving